ABSTRACT
Background Parkinson’s disease (PD) is a neurodegenerative disorder with a significant immune component, as demonstrated by changes in immune biomarkers in patients’ biofluids. However, which specific cells are responsible for those changes is unclear since most immune biomarkers can be produced by various cell types.
Objectives and methods To explore monocyte involvement in PD, we investigated the monocyte-specific biomarker sCD163, the soluble form of the receptor CD163, in cerebrospinal fluid (CSF) and serum in two experiments, and compared it with other biomarkers and clinical data. Potential connections between CD163 and alpha-synuclein were studied in vitro.
Results CSF-sCD163 increased in late-stage PD and correlated with the PD biomarkers alpha-synuclein, Tau, and phosphorylated Tau, while it inversely correlated with the patients’ cognitive scores, supporting monocyte involvement in neurodegeneration and cognition in PD. Serum-sCD163 only increased in female patients, suggesting a sex-distinctive monocyte response. CSF-sCD163 also correlated with molecules associated with adaptive and innate immune system activation and with immune cell recruitment to the brain. Serum-sCD163 correlated with pro-inflammatory cytokines and acute phase proteins, suggesting a relation to chronic systemic inflammation. Our in vitro study showed that alpha-synuclein activates macrophages and induces shedding of sCD163, which in turn enhances alpha-synuclein uptake by myeloid cells, potentially participating in its clearance.
Conclusion Our data present sCD163 as a potential cognition-related biomarker in PD and suggest a role for monocytes both in peripheral and brain immune responses. This may be directly related to alpha-synuclein’s pro-inflammatory capacity but could also have consequences for alpha-synuclein processing.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Samples were obtained from the Neuro-Biobank of the University of Tuebingen, Germany (https://www.hih-tuebingen.de/en/about-us/core-facilities/biobank/), which is supported by the local University, the Hertie Institute and the DZNE. Funding support for the research covered on this article was provided from the Michael J. Fox Foundation (MRR), the Bjarne Saxhof Fund administered through the Danish Parkinson's Foundation (MRR), the Aarhus University Forskningsfond AU IDEAS center NEURODIN (MRR) and the Novo Nordisk Foundation (DEO, NNF17OC0028806). SAF is funded by a PhD fellowship from the PhD School at the Health Faculty, Aarhus University.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IEC University of Tubingen
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Financial disclosure during the past 12 months: M.C. Nielsen has received research grants from Doctor Sofus Carl Emil Friis and Wife Olga Doris Friis’ grant, the Frimodt Heineke Foundation, the Harboe Foundation, Thora and Viggo Groves’ memorial trust, and reagent for the cell study was partly covered by Central Denmark Region.
A. Etzerodt received research support from the Novo Nordisk foundation (NNF).
J. H. Graversen is part of the management of Deliver Pharma and receives support from the Danish National Research Foundation and the NNF.
D. Berg reports advisory board service for Biogen, BIAL, Lundbeck, UCB Pharma GmbH; honoraria from AbbVie, Biogen, BIAL, Lundbeck, UCB Pharma GmbH Zambon, Desitin; and grants from Michael J. Fox Foundation (MJFF), Janssen Pharmaceutica N.V., German Parkinson’s Disease Association (dPV), BMWi, BMBF, Parkinson Fonds Deutschland gGmbH, UCB Pharma GmbH, TEVA Pharma GmbH, EU, Novartis Pharma GmbH, Lundbeck Foundation (LF), Damp foundation.
H.J. Møller received research support from the Danish Innovation Fund and the Danish Central Region.
W. Maetzler is a co-chair of the MDS Technology Task Force and receives or received funding from the EU, the MJFF, Robert Bosch Foundation, Neuroalliance, Lundbeck, and Janssen, and holds part of a patent for assessing dyskinesias (German patent office, 102015220741.2). He received speaker honoraria from GlaxoSmithKline, AbbVie, Bayer, UCB, Licher MT, and Rölke Pharma, and was invited to Advisory Boards of Market Access & Pricing Strategy GmbH, AbbVie, Roche, and Biogen.
A. Panhelainen received research support from the Cure Parkinson’s Trust.
K. Brockmann has received a research grant from the University of Tuebingen (Clinician Scientist), the dPV, the MJFF, and the German Centre for Neurodegenerative Diseases (DZNE, MIGAP); travel grants from the Movement Disorders Society, and speaker honoraria from Abbvie, Lundbeck, UCB, and Zambon.
M. Romero-Ramos serves on the editorial board of Brain Research, and receives research support from NNF, Aarhus University Research Foundation, the Danish Medical Research Council, the Danish Parkinson Foundation, Desiree and Niels Ydes Foundation, and the MJFF.
SKN, SAF, KS, DH, and CS report no disclosures.
Funding Support Funding support for the research covered by this article was provided by the Michael J. Fox Foundation (MRR), the Bjarne Saxhof Fund administered through the Danish Parkinson’s Foundation (MRR), the Aarhus University Research Foundation, AU IDEAS center NEURODIN (MRR), and the Novo Nordisk Foundation (DEO, NNF17OC0028806). SAF is funded by a PhD fellowship from the PhD School at the Health Faculty, Aarhus University. The authors declare no conflict of interest.
This is a revised version, where new statistical analysis have been performed and included in new figures. In addition, new in vitro experiments have been included in this revised version
Data Availability
Qualified investigators can request raw data through corresponding author.
